Group 1: Core Insights - The prevalence of hypertension in China is significant, with an estimated 245 million individuals affected, making hypertension a major risk factor for cardiovascular diseases, which account for nearly 50% of deaths in the country [1] - Current hypertension treatment primarily relies on medication, but adherence is low globally, and the efficacy of antihypertensive drugs is limited for a large population of resistant and uncontrolled hypertension patients [1] - There is an urgent need for new treatment methods beyond medication that can provide long-term and stable blood pressure control [1] Group 2: Advantages of RDN Therapy - RDN (Renal Denervation) is a percutaneous intervention technique that reduces sympathetic nervous system activity by ablating renal artery nerves, leading to long-term blood pressure control [2] - RDN offers all-day blood pressure reduction, good adherence, and relatively low side effects due to its minimally invasive nature [2] - Clinical trials and long-term follow-up studies have confirmed the effectiveness and safety of RDN, with significant milestones achieved in November 2023 when ReCor Paradise and Medtronic Simplicity Spyral received FDA approval [2] Group 3: Current Development and Competitive Landscape of RDN - Multiple RDN products have been approved both domestically and internationally, with significant market potential expected [3] - Internationally, ReCor and Medtronic are leading with FDA approvals, while Boston Scientific has acquired SoniVie to enhance its RDN offerings [3] - In China, by August 2025, four RDN products are expected to be approved, all utilizing radiofrequency ablation, indicating a competitive landscape with opportunities for domestic manufacturers to differentiate through innovation [3]

Group 1 - The core viewpoint is that hypertension is a significant health issue in China, with an estimated 245 million patients, making hypertension control crucial for reducing cardiovascular risks [1] - Renal denervation (RDN) is highlighted as a minimally invasive intervention that effectively controls blood pressure, with its efficacy validated through multiple clinical trials [1] - The approval of Medtronic's Simplicity Spyral and ReCor Paradise by the FDA marks a significant milestone for RDN therapy, indicating growing acceptance and potential for market expansion [1] Group 2 - Four RDN products have been approved in China, with domestic manufacturers innovating in electrode design and access methods to create differentiated advantages [1] - As evidence from evidence-based medicine accumulates, RDN is expected to become a first-line treatment for drug-resistant hypertension, with more multi-energy products being approved domestically and internationally [1] - The Guotai ETF (159377) tracks the Chuangyi Pharmaceutical Index (399275), which includes stocks from the pharmaceutical, medical device, and healthcare services sectors, reflecting the overall performance of innovative growth companies in the biotech industry [1]